Clodronate Disodium Injection

This product is a bone metabolism regulator that can enter the hydroxyapatite crystals in the bone matrix. When osteoclasts dissolve the crystals, the drug is released, which can inhibit the activity of osteoclasts and indirectly inhibit bone resorption through osteoblasts.

The main ingredient of this product is disodium clodronate, and its chemical name is disodium (dichloromethylene) diphosphonate tetrahydrate.

This product is a colorless clear liquid.

1. Hypercalcemia complicated by malignant tumors. 2. Bone pain caused by osteolytic cancer metastasis. 3. Can avoid or delay osteolytic bone metastasis of malignant tumors. 4. Various types of osteoporosis.

1. Paget's disease: 300 mg/day, intravenous drip for more than 3 hours, for 5 days, then oral administration. 2. Hypercalcemia: 300 mg/day, intravenous drip for 3-5 days or 1.5 g intravenous drip once, then oral administration after blood calcium returns to normal.

1 Dizziness and fatigue may occur in a few cases, but they often disappear with continued treatment. The most commonly reported adverse reactions of clodronate are nausea, vomiting, and diarrhea, which occur in about 10% of patients, but these reactions are usually mild and common at high doses. 1 Asymptomatic hypocalcemia is common, and symptomatic hypocalcemia is rare. 2 Dizziness and fatigue may occur in a few cases, but they often disappear with continued treatment; 3 Adverse reactions such as increased serum lactate dehydrogenase and other liver enzyme levels, leukopenia, and abnormal renal function may sometimes occur. 2 Adverse reactions such as increased serum lactate dehydrogenase and other liver enzyme levels, leukopenia, and abnormal renal function may sometimes occur.

1. Patients who are allergic to this product are prohibited from using this product. 2. Patients with severe renal impairment and osteomalacia are prohibited from using this product.

1. Concurrent use with other bisphosphonates is prohibited. 2. When used in combination with nonsteroidal anti-inflammatory analgesics, there are reports of renal insufficiency. 3. When used in combination with aminoglycosides, there is an increased risk of hypocalcemia.

Sealed, stored in a cool, dry place. Valid for 24 months.

5ml:0.3g

Nanjing Pharmaceutical FACTORY Co., Ltd.

• Founded in:

  1991-07-11

• Address:

  No. 26, Xingang Avenue, Nanjing Economic and Technological Development Zone

• Tax NO.:

  91320192134908655F

• Registered Funds:

  200.8 million yuan

• Website:

  Log in to view

• Email:

  Log in to view